Memorial Hospital Research Laboratories
The David Jones Lab
The primary reason that people die from cancer is the development of metastatic disease. My laboratory primarily investigates the underlying genomic, transcriptomic, and signal transduction mechanisms involved in metastasis. As a surgeon-scientist who cares for people with lung, esophageal, and mesothelioma malignancies, I focus my laboratory’s studies on these specific cancers. We have focused a class of genes known as metastasis suppressor genes and, in particular, breast cancer metastasis suppressor I (BRMS1). BRMS1 is a 246aa protein mapped to chromosome 11q13, which functions as a metastases suppressor and has been shown to have functional relevance in breast cancer, melanoma, and lung cancer, among other solid tumors. We have identified important molecular functions of BRMS1 as a transcriptional repressor, an E3 ligase, and a mediator of RelA/p65 transcription in lung cancer in vivo and in vivo models, as well as in mouse models of metastases. We are also studying genomic predictors of recurrence and metastases in lung cancer, RNA editing and the resulting biology, and the development of a circulating tumor cell program. Our lab is fortunate to have access to human cancer tissue with matched normal tissue, which makes many of our patient-derived cancer discovery and validation models feasible.
- Patient-Derived Lung Adenocarcinoma Organoids (PDO) Program
- BRMS1-Mediated Suppression of Metastases in p53 Mutant Lung Adenocarcinoma
- Characterizing the role of the adenosine deaminase acting on RNA (ADAR) gene as a potential oncogene in lung cancer
- Tumor Genomics and Their Application in Early-Stage Lung Cancer
Szymura SJ, Zaemes JP, Allison DF, Clift SH, D’Innocenzi JM, Gray LG, Mckenna BD, morris BB, Bekiranov S, LeGallo RD, Jones DR, Mayo MW. NF-ĸB upregulates glutamine-fructose-6-phosphate transaminase 2 to promote migration in non-small clell lung cancer. Cell Commun Signal 2019;17(1):24.
Forde PM, Chaft JE, Smith KN, Anagnostou V, TCottrell TR, Hellmann MD, Yang SC, Jones DR, Broderick SR, Battafarano R, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Caushi J, Chan HY, Scharpf RB, White J, Gabrielson E, Zahurak M, Rosner G, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378:1976-86.
David R. Jones, MD
- Physician-scientist David R. Jones studies molecular mechanisms governing the development of metastases in lung and esophageal cancers.
- AACR Career Development Award for Translational Research in Lung Cancer 2001
- Member, Tumor Progression and Metastases Study Section NCI; 2010-16 (Chair 2014-16)
- Co-Director, Fiona and Stanley Druckenmiller Center for Lung Cancer Research, MSKCC
- Castle Connolly Top Doctors for Cancer 2010-present
Please contact Dr.
Lung Cancer Biology Fiona and Stanley Druckenmiller Center for Lung Cancer Research Memorial Sloan Kettering Cancer Center, New York, NY In conjunction with the Druckenmiller Center for Lung Cancer Research, the Thoracic Surgery Oncology Research program at MSKCC is searching for an outstanding scientist with a strong interest in translational research focused on the biology of lung cancer metastases.
Postdoctoral Researcher Lung Cancer Biology
Fiona and Stanley Druckenmiller Center for Lung Cancer Research Memorial Sloan Kettering Cancer Center, New York, NY The Jones laboratory, a multi-R01 funded research program, in conjunction with the Druckenmiller Center for Lung Cancer Research, is searching for an outstanding scientist with a strong interest in translational research focused on the biology of lung cancer metastases.
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
David R. Jones discloses the following relationships and financial interests:
Provision of Services
Merck & Co Inc.
Provision of Services (uncompensated)
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.